[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100625861":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":29,"centralContacts":33,"locations":25,"responsibleParty":38,"collaborators":40,"id":43,"slug":25,"hasResults":44,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":49,"sex":50,"minAge":51,"maxAge":25,"enrollmentInfo":52,"targetDuration":25,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":25,"overallStatus":61,"whyStopped":25,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":25},{"fullName":5,"class":6},"University of Alberta","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Active Domain Intervention(s)","EXPERIMENTAL","Participants will be randomized to receive one of the active intervention strategies being evaluated within eligible HEART Platform domains at the time of randomization. Eligible domains and interventions may change over time as domains are initiated, modified, or closed.",[13],"Other: Domain Intervention(s)",{"label":15,"type":16,"description":17,"interventionNames":18},"Control \u002F Standard of Care Comparator","PLACEBO_COMPARATOR","Participants will be randomized to a concurrent control group within eligible HEART Platform domains. The control group may include placebo and\u002For standard-of-care management, as specified in each active domain protocol.",[19],"Other: Control \u002F Standard of Care Comparator",[21,26],{"type":6,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"Domain Intervention(s)","Participants randomized to the experimental arm will receive an intervention being evaluated within an eligible HEART Platform domain at the time of randomization. Domain interventions may change over time as domains are added, modified, or closed in accordance with the platform master protocol and domain-specific protocols.",[9],null,{"type":6,"name":15,"description":27,"armGroupLabels":28,"otherNames":25},"Participants randomized to the comparator arm will receive concurrent control within eligible HEART Platform domains. Control may include placebo and\u002For standard-of-care management, depending on the domain-specific protocol.",[15],[30],{"name":31,"affiliation":5,"role":32},"Justin Ezekowitz, MD","PRINCIPAL_INVESTIGATOR",[34],{"name":31,"role":35,"phone":36,"phoneExt":25,"email":37},"CONTACT","780-492-0712","jae2@ualberta.ca",{"type":39,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR",[41],{"name":42,"class":6},"Canadian VIGOUR Centre","100625861",false,"NCT07428135","Heart Failure Efficacy and Research Trial (HEART) Platform","HEART","Inclusion Criteria (HEART Platform)\n\n* Participants are eligible for inclusion if they meet all of the following:\n* Age ≥18 years (or legal age of majority in participant's country of residence).\n* Diagnosis of heart failure, and eligible to be classified into one of the HEART platform states at the time of randomization:\n* State 1: Worsening Heart Failure (WHF): currently hospitalized for acute decompensated heart failure or emergency department patients requiring intravenous therapy for heart failure; OR\n* State 2: Ambulatory Heart Failure: stable outpatients with established heart failure diagnosis, receiving ongoing HF management and without HF hospitalization within the prior 30 days.\n* Able and willing to provide written informed consent (or consent via a legally authorized representative, where applicable).\n* Meets all applicable domain-specific eligibility criteria for at least one active HEART Platform domain at the time of screening\u002Frandomization.\n\nExclusion Criteria (HEART Platform)\n\n* Participants will be excluded if any of the following apply:\n* Inability to provide informed consent (and no legally authorized representative available when applicable).\n* Not eligible for assignment to either HEART platform state (State 1 or State 2).\n* Presence of conditions or circumstances that, in the investigator's opinion, would make study participation unsafe or not feasible (e.g., inability to comply with study procedures or follow-up).\n* Does not meet the eligibility requirements for any active HEART Platform domain.\n* Any domain-specific exclusion criteria applicable to the intervention\u002Fdomain(s) for which the participant would otherwise be eligible.\n* Additional inclusion and exclusion criteria apply for each individual HEART Platform domain and will be specified in the relevant domain protocol(s).",true,"ALL","18 Years",{"count":53,"type":54},1000,"ESTIMATED","INTERVENTIONAL",[57],"NA","The Heart Failure Efficacy and Research Trial (HEART) Platform is a multicenter, randomized platform study designed to improve outcomes for patients with heart failure through the simultaneous and sequential evaluation of multiple interventions across the spectrum of heart failure.",[60],"Heart Failure","NOT_YET_RECRUITING","2026-06-26",{"date":64,"type":65},"2026-06-30","ACTUAL",{"date":67,"type":54},"2026-07",{"date":69,"type":54},"2037-03",{"name":5,"class":6}]